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Innovations
Archemix
Nucleic Acid Platforms
came this information that looks to selection of nucleic acids to derive
molecules—either as therapeutichave significant value.” It is this work
that led to Archemix’s founding in aptamers or as RiboReporters,”
It all started 4 billion years ago: Ac-
cording to one of the founders of
Archemix, a 35-person drug discov-
ery, biosensors, and biotherapeu- May 2001. says David Epstein, senior director
of research and development attics company in Cambridge, MA, the Two Companies in One
Archemix is a drug discovery andcompany partially owes its creation Archemix. The goal: to identify ther-
apeutically relevant systems andto events that may have been crucial development company focusing on
two enabling technologies. “Whenfor the origin of life itself. targets and build fully integrated
assays around those targets.“There is a controversial theory we formed the company, the idea
was to take these RiboReporters,of how life began and progressed RiboReporters: Bind, Fold,
and Snipcalled the ‘RNA World Theory,’” says build a unique platform for drug dis-
covery, and then develop partner-Ron Breaker, Associate Professor in “RiboReporters are ribozymes mod-
ified to turn on in the presence of anthe Department of Molecular, Cellu- ships using those as tools to help
other companies with their druglar, and Developmental Biology at analyte but are completely off in the
absence of an effector molecule,”Yale University and an Archemix co- discovery programs” says Martin
Stanton, president of Archemix. “Wefounder. “It holds that at one time, says Epstein. They are detection
molecules with an active site as wellbefore the invention of protein and also intended to put our own small-
molecule discovery program intoDNA, RNA molecules served both as as a separate site that binds an ef-
fector. When a target binds the allo-genetic information and as cata- place.” But the research agenda
lysts,” he says. Breaker and col- steric activation domain engineered
into a RiboReporter, it changes theleagues at Yale set out to test one
of the key aspects of the RNA World speed at which the active site works.“Imagine these things likeTheory. That is, if RNA gave rise to Once bound, RiboReporters quickly
gene chips that are smartthe current cellular environment, it cut in a particular position and thus
form two compounds. “They bind towould have had to catalyze many oligonucleotides,” says
reactions. It would have had to be target, fold up, and then cleave,”Ron Breaker, Archemixable to sense both its environment summarizes Breaker. “We can mea-
cofounder, of his com-and how much material it was mak- sure how much RNA has been
cleaved and equate that with howing and turn things on and off at the pany’s RiboReporters.
right time. much target we’ve put into the solu-“They not only bind to“We used in vitro evolution to cre- tion.” The rate at which these RNAs
their unique target, butate entirely new RNA molecules— cleave correlates with the amount of
target in the mixture. “Imagine theseRNA enzymes that would cut them- then they report the fact
selves only when we add a certain things like gene chips,” suggeststhat they’ve bound by do-compound,” says Breaker. What Epstein, “that are smart oligonucleo-
ing a chemical reaction”.they created were RNA molecules tides in that they not only bind to
that catalyzed a reaction when they their unique target, but then they re-
were bound to an effector. “It’s really port the fact they’ve bound by doing
grew sharply in October 2001 whena simple molecular switch,” he con- a chemical reaction.”
Archemix purchased intellectualcludes, referring to compounds also Archemix researchers are ex-
property for aptamer technologycommonly known as allosteric ribo- ploiting the ability of RiboReporter
from Gilead Sciences (Foster City,zymes, or “RiboReporters” in Arch- technology to work in solution, on
CA). Aptamers are modified oligonu-emix parlance. He and others, in- microarrays, and inside cells and
cleotides that bind molecular tar-cluding Andrew Ellington at the cell lysates with the goal of turning
gets, especially proteins. They haveUniversity of Texas at Austin, them into the next generation of bio-
potential for therapeutic and detec-worked on this research for 2–3 detection molecules to replace anti-
tion purposes. “Our focus is nowyears. They made several different bodies. “You can’t do that with an
two-fold: RiboReporters for drugmolecular switches. “Eventually, we antibody,” says Epstein referring to
discovery and aptamer therapeu-theorized that if we can make these the primary competitive technology
for RiboReporters. Comparing thein the lab today and nature made tics,” says Stanton. Both receive
equal time among Archemix’s 15them billions of years ago, maybe two technologies, Epstein says, “In
contrast with an antibody systemwe can make some use out of it in Ph.D.’s.
“We refer to our focus as an evolvedthe commercial setting,” says that always requires three compo-
nents, with a RiboReporter you’reBreaker. “We were asking a very ar- nucleic acid platform because both
programs essentially utilize in vitrocane academic question, and out working with a single molecule cap-
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ture-and-detection system.” He and can track not only the level of a range from 10,000 Da if they are not
coupled to the delivery agent, poly-continues, “I think a lot of people given protein but also its state in real
time. “We’ve shown you can add ahave overlooked nucleic acids as a ethylene glycol (PEG), to 50,000 Da
when PEGylated. Ranging frompowerful detection system and fo- drug to a cell and follow the action
of that drug on a protein target usingcused on antibodies for routine de- 150,000 Da to significantly more,
Monoclonal antibodies are muchtection. They didn’t think of what RiboReporters in this protein PCR
platform.” The power is that one canthey could do if they had a catalytic larger. This means aptamers can be
delivered subcutaneously, whereasplatform, not just a binding platform.” do this inside live cells.
The primary challenges with theArchemix got its start with ribo- intramuscular injections are required
of antibodies. They are less costlyzymes in May 2001 when it licensed RiboReporter technology have been
to industrialize the process and toself-cleaving ribozyme technology to produce—$1,000/gram of ap-
tamer versus $1,000–$10,000/gramfrom Ribozyme Pharmaceuticals, adapt the system to therapeutically
relevant targets. “It isn’t clear whatInc. in Boulder, CO. RPI retains its of antibody—and are easily gener-
ated at the benchtop through in vitrofocus on ribozymes for therapeutic the potential is for these molecular
switches,” cautions Breaker. “Wepurposes. “Researchers at the Uni- selection. “This allows us to engi-
neer in specificity at the same timeversity of Texas and Yale showed know that RNA can fold up and see
many different proteins and organicthey could make ribozymes that that we generate affinity,” says Ep-
stein. A desired consequence isswitch on and off by the presence of compounds, but can we see every-
thing we want? We don’t know yet.”an analyte,” says Stanton. Archemix avoidance of unintended targets
that give rise to side effects and tox-then licensed that technology, plus Aptamers: Nucleic
Acid Antibodiesdetection and other ribozyme plat- icity. “Because the cost is so much
lower, we can reengineer or rede-forms, from Stanton’s previous em- Aptamer technology is not new. Cre-
ated back in 1989 by Larry Gold atployer, Brandeis University, to cre- sign and synthesize and generate an
aptamer much the same way oneate the RiboReporter technology. the University of Colorado, it moved
into NeXstar Pharmaceuticals, whichDetection methods are a current would with a small molecule,” says
Epstein, “plus they have incrediblyfocus of the RiboReporter effort. was purchased by Gilead in 1999.
NeXstar accomplished about 150One can detect the presence of an long half-lives and are stored lyophi-
lized indefinitely at room temp indef-effector by watching the release of patents in the technology develop-
ment, methods of selection and gen-fluorescence by a “molecular bea- initely.” Just add water and you’re
ready to go.con”—an RNA molecule with a fluo- eration, and the entire portfolio of
what constitutes in vitro selection—rescent group on its 5 end and a Archemix is limiting its aptamer
therapeutics portfolio to targets inquenching group on its 3 end. If that known as the SELEX enrichment
process. In addition, the companyRNA forms a hairpin, then the fluo- the extracellular, intravascular com-
partment; such targets includerescent group and quencher are developed methods for serum stabi-
lization and delivery, as well as keynext to each other and there is no growth factors and cytokines. “We
don’t think extravascular is off-limitsor little fluorescence. If the ribozyme patents on biologically relevant tar-
gets. It developed about 20 preclini-comes in and splits that molecule, because of the size,” cautions Ep-
stein, “but we’re clearly not going tothe solution glows. According to cal serum-stabilized candidates,
with six completing pharmacokineticBreaker, “In the future, it would be try get into intracellular space.” They
have yet to firmly select lead ap-great to have a ribozyme immobi- testing and another six shown to be
active in various animal models forlized on a surface or in solution that tamer candidates, but Epstein and
colleagues are building a develop-can be detected by direct electronic diseases such as cancer, rheuma-
toid arthritis, and inflammation.means.” If the ribozyme binds, it cre- ment team to help evaluate the cur-
rent aptamer portfolio as well as theates an electronic signal confirming “We then licensed all this technol-
ogy into an evolved nucleic acidsthe presence of the desired effector. potential for new programs. The
portfolio contains therapeutic targets,In Vivo Biodetection company, which has ribozymes for
drug discovery and now has the“What’s really exciting about this including Platelet Derived Growth
Factor (PDGF), which has alreadytechnology is what we call protein power of serum-stabilized aptam-
ers,” boasts Epstein of the $17.5 mil-PCR. Utilizing the ligase format shown some efficacy in end-stage
renal disease and restenosis, inwhere an effector molecule triggers lion Gilead deal. Archemix is benefit-
ing from recent advances in aptamera ligation and that then allows for which the aptamer blocks binding of
PDGF to its receptor and thus pre-the formation of a PCR product, we stabilization, including modifications
improving delivery and pharmacoki-can then detect ligase activity by vents cell proliferation, matrix accu-
mulation, and subsequent glomeru-quantitative PCR,” says Epstein. netic and therapeutic properties.
The Competition: MonoclonalProtein PCR allows real-time protein lar damage. Aptamers have also
been designed to target other growthexpression profiling of human cells Antibodies
Archemix also sees monoclonaland tissue. The company has devel- factors, selectins, and complement
components.oped the technique to profile gene antibodies, defined internally as
“nucleic acid antibodies,” as the pri-expression at the protein level as op- Archemix is one of three compa-
nies benefiting from Gilead aptamerposed to the mRNA level, which is mary competition to aptamer thera-
peutics. “The key advantage withmore common. Epstein says they licenses. EyeTech Pharmaceuticals
(New York, NY) is taking the first ap-can differentiate between posttrans- aptamers is their size relative to anti-
bodies,” says Epstein. Aptamerslationally modified forms of proteins tamer therapeutic, developed at Gil-
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ead, into clinical trials. The anti-
VEGF drug, EYE001, is now in Phase
II/III for age-related macular degen-
eration. SomaLogic Inc. (Boulder,
CO) is developing an aptamer-based
in vitro diagnostic aptamer array
project capable of simultaneously
detecting 10,000 proteins on one
chip. “We’re not doing that our-
selves,” says Stanton. Instead, the
company intends to focus on low-
throughput, high-value targets for
therapeutics.
Archemix is now passing along
parts of its aptamer technology trea-
sure. In January 2002, the company
made a licensing agreement with
NOXXON Pharma AG for use of the
SELEX process in combination with
its own Speigelmer oligonucleotide
technology. “We can’t possibly de-
rive all of the value from the aptamer
technology ourselves,” says Stan-
ton, “though we’ll certainly take
some therapeutic aptamers all the
way ourselves.” So, if you’re in the
market for a share of the aptamer
patent technology, Archemix is lis-
tening.
Alice McCarthy is a freelance science writer
based in Magnolia, MA (alice@alicemccarthy.
com).
